New drug DM002 enters first human tests for Hard-to-Treat cancers

NCT ID NCT06751329

Recruiting now Disease control Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; second, giving that best dose to more participants to check safety and see if tumors shrink. Participants will have frequent visits and be followed for about 30 days after treatment ends.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma colorectal neoplasm endometrium neoplasm malignant pancreatic neoplasm neoplasm ovarian cancer ovarian neoplasm pancreatic neoplasm prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL NEOPLASMS ENDOMETRIAL NEOPLASMS OVARIAN NEOPLASMS PANCREATIC CANCER PROSTATIC NEOPLASMS SOLID CARCINOMA

Contacts and locations

Locations

Cancer Care Wollongong
RECRUITING

Wollongong, New South Wales, 2500, Australia
Carolina BioOncology Institute, LLC
RECRUITING

Huntersville, North Carolina, 28078, United States
Scientia Clinical Research
RECRUITING

Randwick, New South Wales, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Adelaide, South Australia, Australia
The University of Texas, MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of California San Francisco Cancer Center
RECRUITING

San Francisco, California, 94158, United States
University of Oklahoma Health Sciences Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.